- PBGENE-HBV selected for late-breaking oral at AASLD The Liver Meeting 2026
- Presentation: Sunday Nov 8, 2:15-2:30 PM MST
- Abstract title: Durable pgRNA loss in both HBeAg positive and negative patients treated with PBGENE-HBV supports path towards viral cure
- PBGENE-HBV targets and eliminates cccDNA
- FDA Fast Track designation granted
- ELIMINATE-B Phase 1 trial enrolling HBeAg negative and positive patients globally
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card